EMA Authorised: Axura (memantine hydrochloride) — Merz Pharmaceuticals GmbH

View source ↗

Summary

EMA authorised Axura (memantine hydrochloride) by Merz Pharmaceuticals GmbH for the treatment of Alzheimer disease. This marks EU marketing authorization for th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Axura (memantine hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Alzheimer Disease. MAH: Merz Pharmaceuticals GmbH. Decision date: 19/06/2025